Table 1.
Baselines Characteristics of Pregnant Study Participants Who Were Randomly Assigned to Receive Efavirenz (EFV)–Based Antiretroviral Therapy (ART) or Lopinavir/Ritonavir (LPV/r)–Based ART
| Characteristic | Treatment Arm |
P Value | |
|---|---|---|---|
| EFV-Based ART (n = 195) | LPV/r-Based ART (n = 194) | ||
| Age, y | 29.5 ± 5.4 | 29.0 ± 5.4 | .31 |
| Gestational age, wk | 21.1 ± 4.1 | 21.2 ± 4.3 | .91 |
| Previous pregnancies | |||
| 0 | 16 (8.2) | 8 (4.1) | .20 |
| 1 | 20 (10.3) | 25 (12.9) | |
| ≥2 | 159 (81.5) | 161 (83.0) | |
| Bed net ownership | |||
| None | 85 (43.6) | 85 (44.3) | .84 |
| Untreated | 28 (14.4) | 33 (17.2) | |
| ITN | 77 (39.5) | 70 (36.4) | |
| Yes; unknown treatment status | 5 (2.5) | 4 (2.1) | |
| Receiving TMP-SMX prophylaxis | 125 (64.1) | 124 (63.9) | .97 |
| Hemoglobin level, g/dL | 10.9 ± 1.3 | 11.0 ± 1.2 | .82 |
| CD4+ T-cell count, cells/mm3 | 374 (270–485) | 368 (282–506) | .31 |
| HIV RNA load, log10 copies/mL | 4.3 (3.5–4.8) | 4.1 (3.3–4.7) | .35 |
| WHO stage HIV disease | |||
| 1 | 181 (92.8) | 189 (97.4) | .09 |
| 2 | 13 (6.7) | 5 (2.6) | |
| 3 | 1 (0.5) | 0 | |
Data are no. (%) of participants, mean ± SD, or median (interquartile range).
Abbreviations: HIV, human immunodeficiency virus; TMP-SMX, trimethoprim-sulfamethoxazole; WHO, World Health Organization.